Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1992-04-14
1993-07-20
Wityshyn, Michael G.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 851, A61K 4505
Patent
active
052291090
ABSTRACT:
The properties of two recombinant human IL-2 analogues with mutations at Arginine 38 (.fwdarw.Alanine) and Phenylalanine 42 (.fwdarw.Lysine) were analyzed and compared to those of native IL-2. These analogues were found to maintain their ability to bind to the intermediate IL-2 receptor, p75, while binding only minimally to the high affinity p55+p75 receptor complex. The analogues also maintained the ability to stimulate peripheral blood mononuclear cells to generate lymphokine activated killing (LAK). However, IL-1.beta. and TNF-.alpha. secretion were significantly reduced in response to the analogues, as compared to the native IL-2 molecule. These analogues are therefore potentially valuable low-toxicity alternatives to IL-2 in human immunotherapy and adoptive immunotherapy treatment strategies.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 4863740 (1989-09-01), Kissel et al.
patent: 4999339 (1991-03-01), Paradise et al.
patent: 5037644 (1991-08-01), Shaked et al.
patent: 5066489 (1991-11-01), Paradise et al.
patent: 5098702 (1992-03-01), Zimmerman et al.
patent: 5102872 (1992-04-01), Singh et al.
L. Collins et al., "Identification of Specific Residues of Human Interleukin 2 That Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," Proceedings of the National Academy of Science USA, 85:7709-7713, 1988.
Grace Ju et al., "Structure-Function Analysis of Human Interleukin-2, Identification of Amino Acid Residues Required for Biological Activity," The Journal of Biological Chemistry, 262(12):5723-5731, 1987.
Steven A. Rosenberg, M. D., Ph.D. et al., "Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients,"Annals of Surgery, 210:474-485, 1989, Abstract Only.
K. Sauve et al., "Localization in Human Interleukin 2 of the Binding Site to the .alpha. Chain (p55) of the Interleukin 2 Receptor," Proceedings of the National Academy of Science USA, 88:4636-4640, 1991.
Ulrich Weigel et al., "Mutant Proteins of Human Interleukin 2," European Journal of Biochemistry, 180:295-300, 1989.
M. P. Weir et al., "Structure-Activity Relationships of Recombinant Human Interleukin 2," Biochemistry, 27:6883-6892, 1988.
Sandra M. Zurawski et al., "Mouse Interleukin-2 Structure-Function Studies: Substitutions in the First .alpha.-Helix Can Specifically Inactivate p70 Receptor Binding and Mutations in the Fifth .alpha.-Helix Can Specifically Inactivate p55 Receptor Binding," The EMBO Journal, 8(9):2583-2590, 1989.
Grant et al., "The Interleukin 2 Receptor (IL-2R): The IL-2R .alpha. Subunit Alters the Function of the IL-2R .beta. Subunit to Enhance IL-2 Binding and Signaling by Mechanisms That Do Not Require Binding of IL-2 to IL-2R .alpha. Subunit," Proc. Natl. Acad. Sci. USA, 89:2165-2169, 1992.
Landgraf et al., "Conformational Perturbation of Interleukin-2: A Strategy for the Design of Cytokine Analogs," Proteins: Structure, Function, and Genetics, 9:207-216 (1991).
Boone et al., "Interleukin-2 Analogs," Dev. Biol. Stand., 69:157-168, 1988, abstract only.
Grimm Elizabeth A.
Heaton Keith
Board of Regents , The University of Texas System
Koh Choon
Wityshyn Michael G.
LandOfFree
Low toxicity interleukin-2 analogues for use in immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Low toxicity interleukin-2 analogues for use in immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low toxicity interleukin-2 analogues for use in immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1758846